Personalized genes therapy treatment involves adapting genetic intervention based on a person’s unique genetic makeup for treating diseases at their source or potentially treatment. This approach enables highly targeted treatments with better efficacy and low side effects. The market is growing rapidly due to progress in genomics, increasing the prevalence of genetic and rare diseases, increasing demand for accurate medicine and assistant regulatory structure. Innovation in CRISPR, viral vectors and next generation sequencing is also accelerating the development and adoption of individual gene therapy.
Key Growth Drivers and Opportunities
Increasing the Prevalence of Genetic and Rare Diseases: Increasing prevalence of genetic and rare diseases is a major driver of the individual gene therapy market, as traditional treatments often fail to address the root cause of these complex conditions. The gene therapy provides the ability of long -term or remedial solutions by targeting the defective genes directly. As more patients are diagnosed through advanced genetic testing, the demand for effective treatments increases. This growing patient pool encourages investment and innovation in individual gene remedies, accelerating market expansion.
Challenges
Personalized gene therapy treatment faces several boundaries including high growth and treatment costs, complex manufacturing processes and limited access to low- and medium-income areas. Regulatory barriers, moral concerns, and potential security risk such as immune response or off-target effects also face challenges. Additionally, advanced genetic testing and special infrastructure requirement can restrict the extensive adoption, especially in lowly developed health care systems.
Innovation and Expansion
Philadelphia’s Children’s Hospital Creates History with the First Customized CRISPR Gene Therapy
In May 2025, A team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine has made medical history by successfully treating a kid with a rare genetic disease using a personalized CRISPR gene editing treatment.
Gene editing based on CRISPR (clustered regularly interspaced short palindromic repeats) may accurately fix variations in the human genome that cause illness. Up until now, researchers have developed gene editing technologies to target more prevalent diseases that impact tens or hundreds of thousands of people, including the two disorders for which there are presently U.S.
Bharat Biotech Aims for a 2028 Product Launch After Revealing Cell and Gene Therapy Facility
In March 2025, In the southern Indian state of Telangana, the Indian vaccine manufacturer Bharat Biotech stated that it has spent USD 75 million in its first cell and gene therapy (CGT) facility. The company anticipates that its novel treatments will be available for purchase within the next three years.
The firm is shifting its focus from its primary business of vaccines to complicated cell and gene therapy, a market that is predicted to more than five times rise from USD 21.28 billion in 2024 to USD 117.46 billion by 2034.
Inventive Sparks, Expanding Markets
The key players operating the personalized gene therapy treatment include Amgen, Inc., Chengdu Shi Endor Biological Engineering Technology Co., Ltd., and others. R&D innovation, strategic alliances, focusing on rare illnesses, growing clinical trials, utilizing cutting-edge genomic techniques, and obtaining regulatory clearances are important growth tactics.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
